Author:
Yu Yue,Gu Fang,Luo Yi-Lin,Li Shi-Guang,Jia Xiao-Feng,Gu Liang-Xian,Zhang Guo-Ping,Liao Xin
Abstract
Abstract
Background
Solitary fibrous tumors (SFT) and meningiomas (MA) have similar clinical and radiographic presentations but require different treatment approaches and have different prognoses. This emphasizes the importance of a correct preoperative diagnosis of SFT versus MA.
Objective
In this study, investigated the differences in imaging characteristics between SFT and MA to improve the accuracy of preoperative imaging diagnosis of SFT.
Methods
The clinical and imaging data of 26 patients with SFT and 104 patients with MA who were pathologically diagnosed between August 2017 and December 2022, were retrospectively analyzed. The clinical and imaging differences between SFT and MA, as well as between the various pathological grades of SFT, were analyzed.
Results
Age, gender, cystic change, flow void phenomenon, yin-yang sign, lobulation, narrow base, tumor/cortex signal ratio (TCSR) > 1.0 in T1-weighted imaging (T1WI), TCSR ≥ 1.1 in T2-weighted imaging (T2WI), peritumoral edema, and absence of dural tail sign varied between SFT and MA. As per the receiver operating characteristic (ROC) curve analysis, TCSR > 1 in T1WI has the maximum diagnostic accuracy for SFT. Cranial or venous sinus invasion had a positive effect on SFT (Grade III, World Health Organization (WHO) grading).
Conclusion
Among the many radiological and clinical distinctions between SFT and MA, TCSR ≥ 1 exhibits the highest predictive efficacy for SFT; while cranial or venous sinus invasion may be a predictor of WHO grade III SFT.
Funder
the National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Smrke A, Thway K, Huang PH, et al. Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma. Future Oncol. 2021;17(27):3627–36.
2. Wang K, Mei F, Wu S, et al. Hemangiopericytoma: incidence, treatment, and prognosis analysis based on SEER database. Biomed Res Int. 2020;2020:2468320.
3. Komori T. The 2016 WHO classification of tumours of the central nervous system: the major points of revision. Neurol Med Chir. 2017;57(7):301–11.
4. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51.
5. Apra C, Mokhtari K, Cornu P, et al. Intracranial solitary fibrous tumors/hemangiopericytomas: first report of malignant progression. J Neurosurg. 2018;128(6):1719–24.